Latest News
Agios Pharmaceuticals, Inc.
- Agios Pharmaceuticals, Inc. Estimates – SWB:8AP
- Form 144 AGIOS PHARMACEUTICALS For: 21 October By Investing.com
- Form 144 AGIOS PHARMACEUTICALS For: 22 October By Investing.com
- Is Agios Pharmaceuticals (AGIO) Undervalued On Hopes For A Mitapivat FDA Decision?
- Why Did Agios Pharmaceuticals (NASDAQ:AGIO) Rise 7.41% Before a November 1 FDA Decision on Mitapivat in Sickle Cell Disease?
- GlaxoSmithKline, Inovio, and Agios are all awaiting review, as U.S. biotech stocks enter an FDA approval window for innovative drugs.
- GlaxoSmithKline (GSK.US), Inovio (INO.US), and Agios (AGIO.US) are among a cluster of companies awaiting review, as U.S. innovative drugs enter an FDA approval window.
- How Investors May Respond To Agios Pharmaceuticals (AGIO) Sickle Cell FDA Review
- Cantor Fitzgerald reiterates Agios Pharma stock rating ahead of PDUFA
- Agios Pharmaceuticals (AGIO) Screens As Undervalued, Can Its Rare Disease Pipeline Justify The Gap?
- Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
- Agios Pharmaceuticals (AGIO) Slides 2.09% to $31.80 as Shares Drift Toward Key Support - Option Strike Build
Headlines from the last 30 days, linking to the original publishers. See all market news →